Skip to main content
OpenTrials
Completed

NCT Number: NCT05046158

Diabetic Foot Ulcers-Comparing Transforming Powder to Standard of Care

Phase IV, randomized, prospective, multi-center, open-label, comparison of transforming powder dressing to standard of care dressing for healing diabetic foot ulcers.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–89 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

MedStar Georgetown University Hospital, Washington D.C., District of Columbia, United States

Loading trial locations.

About this study

Diabetic men and women aged 18-89 years, who have a diabetic foot ulcer present for a minimum of 30 days will be considered for the study. Subjects will be randomized to either standard of care wound dressings or transforming powder dressing. Half of the subjects will receive standard of care dressings, and the other half will receive transforming powder dressing in a 1:1 randomization process at each of the study sites. Subjects will present to the study center weekly for up to 12 weeks (less time if the wound heals prior to 12 weeks). The last study visit occurs 12 weeks after the End of Study visit.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 18-89 years old
  • Diagnosed with diabetes Mellitus; hemoglobin A1C < 12%
  • Diabetic foot ulcer present for minimum 30 days (Wagner grade 1 or 2 classification)
  • Wound drainage is minimal or moderate
  • No clinically active wound infection
  • Able and willing to provide consent
  • Has not participated in another research trial within 3 months of enrollment.

Exclusion criteria

  • Unable to keep weekly research appointments
  • Unable or unwilling to use offloading device if recommended
  • Wounds with large amount (high) drainage
  • Active gangrene
  • Wounds impending surgical intervention (including revascularization or plastic surgery)
  • Untreated osteomyelitis
  • Soft tissue infection (can be enrolled once infection is cleared)
  • Active Charcot arthropathy
  • BMI >45kg/m2
  • History of AIDS
  • History of organ transplant or impending transplant
  • End stage renal disease requiring dialysis
  • Decompensated hepatic or cardiac disease
  • Select autoimmune diseases
  • Lymphedema
  • Oral steroid use in last 3 months
  • Venous stasis disease
  • Active malignancy (cancer)
  • Unable to sign consent
  • Active alcohol or substance abuse
  • Pregnant or lactating women
  • Insufficient vascular flow to heal a wound
  • Hemoglobin A1C >12%

Treatment and study plan

Transforming Powder Dressing

Device

Altrazeal transforming powder dressing is methacrylate-based powder dressing made from the same materials used in the production of contact lenses. Upon hydration, the powder transforms into a moist, non-occlusive barrier that covers and protects the wound from exogenous bacteria while helping manage exudate through vapor transpiration.

Other names: Altrazeal

Standard of care topical wound agents and dressings

Other

Standard wound dressings such as gauze or foams. Moisture regulating topical agents may also be used to prepare the wound bed.

Primary outcomes

  1. Incidence of wound closure

    Time frame: 12 weeks

    Compare rate of complete wound healing in diabetic foot wounds between the two study groups

Secondary outcomes

  1. Wound healing trajectories and time to wound closure

    Time frame: 12 weeks

    Evaluate differences in wound healing trajectories and time to wound closure between the two study groups

  2. Adverse Events

    Time frame: 12 weeks

    Safety as indicated by adverse events (new or worsening conditions) and frequency of wound infections

  3. Subject Satisfaction

    Time frame: 12 weeks

    Evaluate subject satisfaction of wound care products based on "Research subject satisfaction survey" completed at the end of study (8 questions total using a 7 point Likert scale).

  4. Wound pain

    Time frame: 12 weeks

    Compare differences in pain between the groups based on results of a validated 10 point "Visual Analogue Pain Scale" completed at each visit by all subjects. More pain is indicated by higher scores.

  5. Quality of Life while living with a wound

    Time frame: 12 weeks

    Compare differences in quality of life between the groups based on results of completed validated "Wound Quality of Life Questionnaire for Chronic Wounds" (17 questions total, answering a 5 point scale [not at all to very much], results from answers based on formula)

  6. Clinician Acceptability

    Time frame: 12 weeks

    Based on clinician survey completed at end of study (8 questions total, multiple choice or 7 point Likert scale)

Sponsors and collaborators

Lead sponsor

ULURU Inc.

Industry

Collaborators

  • Military Technology Enterprise Consortium (US)
  • Naval Medical Research Center

Registry information

Official study title

Randomized Clinical Trial to Compare Transforming Powder and Standard of Care Dressing Therapies to Heal Diabetic Foot Ulcers

Important dates

Study start
2021
Primary completion
2025
Study completion
2025
First posted
Sep 16, 2021
Registry last updated
Nov 19, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.